An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives

Ghosh, Arijit; Kar, Paritosh k.; Gautam, Anupam; Gupta, Rahul; Singh, Rajveer; Chakravarti, Rudra; Ravichandiran, V.; dastidar, Subhra Ghosh; Ghosh, Dipanjan; Roy, Syamal

doi:10.1039/d2md00009a

Cited by 5 publications

(3 citation statements)

References 242 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RBD has greater affinity for ACE-2 on cells of the ileum, kidney, heart, brain, lung, and vasculatures. It is responsible for the different manifestations it has, including respiratory disease and mild pneumonia; its usual symptoms include fever, shortness of breath, cough, and fatigue [ 3 ]. Besides systemic manifestation, accumulating reports indicate that patients with COVID-19 may develop a variety of neuropsychiatric conditions during or after COVID-19 ( Figure 1 ) [ 4 , 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 on Neuropsychiatric Disorders

Zia

Ravanfar

Allahdadian

et al. 2022

JCM

View full text Add to dashboard Cite

Since the Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many studies have shown that besides common COVID-19 symptoms, patients may develop various neuropsychiatric conditions including anxiety, mood disorders, psychosis, neurodegenerative diseases (e.g., dementia), insomnia, and even substance abuse disorders. COVID-19 can also worsen the patients underlying neuropsychiatric and neurodevelopmental conditions during or after the system phase of disease. In this review, we discuss the impact of SARS-CoV-2 infection on development or status of neuropsychiatric conditions during or following COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 on Neuropsychiatric Disorders

Zia

Ravanfar

Allahdadian

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…To treat patients with new coronavirus pneumonia, scientists have made considerable efforts in drug research and development; however, to date, there are still very few drugs that can treat COVID-19 ( 7 ). Although some neutralizing antibodies and small molecule inhibitors are being developed, there is uncertainty about their safety and efficacy ( 8 ). Therefore, we urgently need to explore new strategies to treat COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Tea Ingredients Have Anti-coronavirus Disease 2019 (COVID-19) Targets Based on Bioinformatics Analyses and Pharmacological Effects on LPS-Stimulated Macrophages

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused millions of deaths and lacks treatment. Although several studies have focused on the major component of green tea, epigallocatechin 3-gallate (EGCG), which is efficient in preventing COVID-19, systemic analyses of the anti-COVID-19 potential of green tea remain insufficient. Here, we co-analyzed the target genes of tea ingredients and COVID-19 signature genes and found that epigallocatechin 3-acetalbehyde was capable of reversing the major molecular processes of COVID-19 (MAPK and NF-κB activation). These findings were further supported by Western blotting (WB), immunofluorescence, and quantitative polymerase chain reaction (qPCR) in LPS-stimulated macrophages. Moreover, using molecular docking analysis, we identified three tea ingredients ((-)-catechin gallate, D-(+)-cellobiose, and EGCG) that may interact with the vital SARS-CoV-2 protein, 5R84, compared with the qualified 5R84 ligand WGS. Thus, our results indicated that tea ingredients have the potential to treat COVID-19 by suppressing the COVID-19 signature genes and interacting with the vital SARS-CoV-2 protein.

show abstract

“…To treat patients with new coronavirus pneumonia, scientists have made considerable efforts in drug research and development; however, to date, there are still very few drugs that can treat COVID-19 (7). Although some neutralizing antibodies and small molecule inhibitors are being developed, there is uncertainty about their safety and efficacy (8). Therefore, we urgently need to explore new strategies to treat COVID- 19.…”

Section: Introductionmentioning

confidence: 99%

Image_1.PDF

View full text Add to dashboard Cite

An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives

Abstract: SARS CoV 2, the virus responsible for the pandemic has been confirmed to be a new coronavirus having 79% and 50% similarity with SARS CoV and MERS CoV respectively. For...

Cited by 5 publications

References 242 publications

Impact of COVID-19 on Neuropsychiatric Disorders

Impact of COVID-19 on Neuropsychiatric Disorders

Tea Ingredients Have Anti-coronavirus Disease 2019 (COVID-19) Targets Based on Bioinformatics Analyses and Pharmacological Effects on LPS-Stimulated Macrophages

Image_1.PDF

Contact Info

Product

Resources

About